Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Baxter
Boehringer Ingelheim
QuintilesIMS
Chubb
Accenture
Merck
Farmers Insurance
US Department of Justice

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XIFAXAN

« Back to Dashboard

Clinical Trials for Xifaxan

Trial ID Title Status Sponsor Phase Summary
NCT00269399 A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Completed Valeant Pharmaceuticals International, Inc. Phase 3 The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
NCT00603616 Induction of Clinical Response Using Rifaximin in Crohn's Disease Recruiting Valeant Pharmaceuticals International, Inc. Phase 2 Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
NCT00603616 Induction of Clinical Response Using Rifaximin in Crohn's Disease Recruiting Scott Lee Phase 2 Antibiotics have been used to treat Crohn's disease symptoms with the best studied antibiotics being Cipro and Flagyl. Rifaximin is a poorly absorbed oral antibiotic that is FDA approved for travelers' diarrhea. It works by inhibiting bacterial reproduction. It is very poorly absorbed and over 97% of the drug taken orally is excreted in the feces. The purpose of this study is to evaluate the potential benefits and safety of Rifaximin for the treatment of moderate to severe symptoms of Crohn's Disease.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Xifaxan

Condition Name

Condition Name for Xifaxan
Intervention Trials
Cirrhosis 4
Hepatic Encephalopathy 2
Diarrhea 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Xifaxan
Intervention Trials
Diarrhea 5
Syndrome 3
Irritable Bowel Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Xifaxan

Trials by Country

Trials by Country for Xifaxan
Location Trials
United States 70
China 3
Norway 2
Germany 2
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Xifaxan
Location Trials
California 6
Florida 4
Washington 3
Virginia 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Xifaxan

Clinical Trial Phase

Clinical Trial Phase for Xifaxan
Clinical Trial Phase Trials
Phase 4 5
Phase 3 5
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Xifaxan
Clinical Trial Phase Trials
Completed 12
Recruiting 11
Withdrawn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Xifaxan

Sponsor Name

Sponsor Name for Xifaxan
Sponsor Trials
Valeant Pharmaceuticals International, Inc. 8
Shanghai Zhongshan Hospital 3
Mayo Clinic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Xifaxan
Sponsor Trials
Other 29
Industry 11
U.S. Fed 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Cantor Fitzgerald
Deloitte
Citi
McKinsey
Cipla
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.